Melasma
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Icho chiitiko chinowanzoitika muvakadzi vekuAsia mukutanga kwavo makumi mana. Chironda chakatenderedzwa mumufananidzo chiri padyo ne lentigo pane melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Munguva pfupi yapfuura, low-fluence Q-switched Nd:YAG (LFQSNY) laser yave yakakurumbira pakurapa melasma, kunyanya muAsia. Kupfupisa zvidzidzo zvakasiyana-siyana kwainetsa, asi LFQSNY inoita kunge inoshanda uye yakachengeteka kune melasma kana ichienzaniswa nekurapa kwechinyakare. Nekudaro, zvimwe zviitiko zvemottled hypopigmentation zvakataurwa sepadivi mhedzisiro yeLFQSNY, pamwe nekuda kwekukwira kwelaser simba. Kushandisa zvine hukasha kweLFQSNY kunogona zvakare kutungamira kune hyperpigmentation kubva mukuzvimba, kunyanya mumatoni akasviba eganda.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Matambudziko epigmentation anowanzo kuwanikwa mukutarisira kwekutanga. Mhando dzakajairika dze hyperpigmentation kusagadzikana dzinosanganisira post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Melasma haigone kugadziriswa nelaser kurapwa kweimwe nguva yenguva, sezvo iri chirwere umo pigment inoramba ichigadzirwa. Tranxenemic acid inobatsira kuvandudza kuderedza pigmentation.
○ Kurapa
Mune dzimwe nyika (semuenzaniso Japan, Korea), oral tranexamic acid inowanikwa pamusoro pekaunda uye inoshanda. Iyo melasma cream ine tranexamic acid uye azelaic acid inogona kubatsira zvishoma.
Hydroquinone inogona kushandiswa pamusoro kurapa hyperpigmentation, asi FDA yakamisa zvigadzirwa zveOTC zvine hydroquinone kubva muna 2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma